

# BBS Seminar

## *Quantitative Benefit-Risk: What Matters to Whom and How? - Getting the Values and Weights Right*

Thursday, 21 July 2011  
Bildungszentrum 21  
Missionsstrasse 21  
4003 Basel




1

## Benefit-Risk Assessment

- Quantitative vs Qualitative approaches
- Transparency of decision making process
- Reproducibility and consistency of decisions
- Implicit vs explicit assumptions regarding weights and values
- How to cope with subjective decisions and judgments?
- Who's values and weights matter?
- How to elicit and use values and weights in a formalized manner?

# Value Tree for BRAT Triptan Example

Full tree with identified and potential outcomes



Source: PhRMA-BRAT

BBS - 21 July 2011

Quantitative Benefit-Risk

3

## Scientific Program

**John Ferguson** (Novartis Vaccines and Diagnostics, USA):

*Structured Benefit-Risk Optimization (BRO):*

*A Framework Quantitative Decision Support Tools*

**Gordon Francis** (Novartis Pharma, USA):

*Clinical Perspective on Benefit-Risk Assessments*

**Lawrence Phillips** (The London School of Economics and Political Science, UK):

*Quantitative Benefit-Risk: Determining Values & Assessing Weights*

**Andrea Beyer** (University Medical Center Groningen, NL):

*Beyond the Probability of Risk: Measuring Perception, Preferences and Values for Health States*

BBS - 21 July 2011

Quantitative Benefit-Risk

4